GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

My elderly mother-in-law is all the rage with charitable groups. Particularly the ones that are opaque at best, and deceptive ...

Long before any campaign gets started, the one-payer idea is drawing criticism from Colorado groups representing insurers and ...

Lt. Gov. Winsome Earle-Sears is the Republican nominee in Virginia’s closely watched governor’s race, but so far has been ...

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

A group of 42 representatives, led by Ocasio-Cortez and Doggett, raised concerns over private company involvement and AI use ...

The groups that pushed for Planned Parenthood to lose Medicaid reimbursement remain confident that a federal judge's ruling ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...